Spironolactone

NIOSH table

Table 2 Non-antineoplastic — eligible for a documented Assessment of Risk.

AHFS classification

24:32.20 mineralocorticoid (aldosterone) receptor antagonists; 24:08.24.16 potassium-sparing diuretics; 24:08.44.20 mineralocorticoid (aldosterone) receptor antagonists; 40:28.16 potassium-sparing diuretics

Screen the current package insert

This page reports this drug’s status on the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. It is not a hazard determination and not a handling instruction. Your facility makes its own Assessment of Risk under USP <800>. Package-insert content changes when the manufacturer revises the label — always screen the current insert before relying on it.